A citation-based method for searching scientific literature

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Daniel Sanghoon Shin, Jesse M Zaretsky, Helena Escuin-Ordinas, Angel Garcia-Diaz, Siwen Hu-Lieskovan, Anusha Kalbasi, Catherine S Grasso, Willy Hugo, Salemiz Sandoval, Davis Y Torrejon, Nicolaos Palaskas, Gabriel Abril Rodriguez, Giulia Parisi, Ariel Azhdam, Bartosz Chmielowski, Grace Cherry, Elizabeth Seja, Beata Berent-Maoz, I Peter Shintaku, Dung T Le, Drew M Pardoll, Luis A Diaz, Paul C Tumeh, Thomas G Graeber, Roger S Lo, Begoña Comin-Anduix, Antoni Ribas. Cancer Discov 2017
Times Cited: 667



Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Jesse M Zaretsky, Angel Garcia-Diaz, Daniel S Shin, Helena Escuin-Ordinas, Willy Hugo, Siwen Hu-Lieskovan, Davis Y Torrejon, Gabriel Abril-Rodriguez, Salemiz Sandoval, Lucas Barthly, Justin Saco, Blanca Homet Moreno, Riccardo Mezzadra, Bartosz Chmielowski, Kathleen Ruchalski, I Peter Shintaku, Phillip J Sanchez, Cristina Puig-Saus, Grace Cherry, Elizabeth Seja, Xiangju Kong, Jia Pang, Beata Berent-Maoz, Begoña Comin-Anduix, Thomas G Graeber, Paul C Tumeh, Ton N M Schumacher, Roger S Lo, Antoni Ribas. N Engl J Med 2016
Times Cited: 1674




List of shared articles



Times cited

Therapeutic applications of the cancer immunoediting hypothesis.
Rupen Desai, Andrew T Coxon, Gavin P Dunn. Semin Cancer Biol 2022
2

Predictive biomarkers for response to immune checkpoint inhibition.
Benjamin Shum, James Larkin, Samra Turajlic. Semin Cancer Biol 2022
17

Interferon-γ: teammate or opponent in the tumour microenvironment?
Angela M Gocher, Creg J Workman, Dario A A Vignali. Nat Rev Immunol 2022
25

IFNγ signaling integrity in colorectal cancer immunity and immunotherapy.
Wan Du, Timothy L Frankel, Michael Green, Weiping Zou. Cell Mol Immunol 2022
2

Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity.
Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo. J Histochem Cytochem 2022
0

IFNγ Signaling in Natural and Therapy-Induced Antitumor Responses.
Alex Martínez-Sabadell, Enrique J Arenas, Joaquín Arribas. Clin Cancer Res 2022
2

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.
Roni Shouval, Ana Alarcon Tomas, Joshua A Fein, Jessica R Flynn, Ettai Markovits, Shimrit Mayer, Aishat Olaide Afuye, Anna Alperovich, Theodora Anagnostou, Michal J Besser,[...]. J Clin Oncol 2022
3

A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
Stefania Bellone, Dana M Roque, Eric R Siegel, Natalia Buza, Pei Hui, Elena Bonazzoli, Adele Guglielmi, Luca Zammataro, Nupur Nagarkatti, Samir Zaidi,[...]. Cancer 2022
3

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.
Felicity Newell, Ines Pires da Silva, Peter A Johansson, Alexander M Menzies, James S Wilmott, Venkateswar Addala, Matteo S Carlino, Helen Rizos, Katia Nones, Jarem J Edwards,[...]. Cancer Cell 2022
6

Spotlight on TAP and its vital role in antigen presentation and cross-presentation.
Ian Mantel, Barzan A Sadiq, J Magarian Blander. Mol Immunol 2022
2

Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.
Uasim Harkus, Miriam Wankell, Pranavan Palamuthusingam, Craig McFarlane, Lionel Hebbard. Semin Cancer Biol 2022
0

APLNR Regulates IFN-γ signaling via β-arrestin 1 mediated JAK-STAT1 pathway in melanoma cells.
Yingying Liu, Xiaochuan Ma, Hui Yang, Xun Li, Yingli Ma, Brandon Ason, Suling Liu, Liaoyuan A Hu. Biochem J 2022
0

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.
Wenjing Zhang, Yujia Kong, Yuting Li, Fuyan Shi, Juncheng Lyu, Chao Sheng, Suzhen Wang, Qinghua Wang. Front Immunol 2022
0

Immune checkpoint inhibitors for the treatment of melanoma.
Francesco Sabbatino, Luigi Liguori, Stefano Pepe, Soldano Ferrone. Expert Opin Biol Ther 2022
0

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.
Junyu Long, Dongxu Wang, Anqiang Wang, Peipei Chen, Yu Lin, Jin Bian, Xu Yang, Mingjun Zheng, Haohai Zhang, Yongchang Zheng,[...]. Genome Med 2022
1

Biomarkers of response to PD-1 pathway blockade.
Hanxiao Li, P Anton van der Merwe, Shivan Sivakumar. Br J Cancer 2022
0

Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.
Samuel S Freeman, Moshe Sade-Feldman, Jaegil Kim, Chip Stewart, Anna L K Gonye, Arvind Ravi, Monica B Arniella, Irena Gushterova, Thomas J LaSalle, Emily M Blaum,[...]. Cell Rep Med 2022
0

Co-occurrence of CDKN2A/B and IFN-I homozygous deletions correlates with an immunosuppressive phenotype and poor prognosis in lung adenocarcinoma.
Yuan Peng, Yonghong Chen, Mengmeng Song, Xiaoyue Zhang, Pansong Li, Xian Yu, Yusheng Huang, Ni Zhang, Liyan Ji, Lei Xia,[...]. Mol Oncol 2022
0

Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions.
Alexander F Haddad, Jacob S Young, Sabraj Gill, Manish K Aghi. Semin Cancer Biol 2022
2

Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response.
Brandie C Taylor, Justin M Balko. Front Immunol 2022
1

Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response.
Tristan Rupp, Laurie Genest, David Babin, Christophe Legrand, Marion Hunault, Guillaume Froget, Vincent Castagné. Transl Oncol 2022
0

The evolutionary legacy of immune checkpoint inhibitors.
Itishree Kaushik, Sharavan Ramachandran, Carson Zabel, Shreyas Gaikwad, Sanjay K Srivastava. Semin Cancer Biol 2022
2

Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance.
Adithya Balasubramanian, Thomas John, Marie-Liesse Asselin-Labat. Biochem Soc Trans 2022
0

B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy.
Chenzhi Zhang, Dandan Li, Binyi Xiao, Chi Zhou, Wu Jiang, Jinghua Tang, Yuan Li, Rongxin Zhang, Kai Han, Zhenlin Hou,[...]. J Immunother 2022
0

Mismatch repair deficiency and clinical implications in prostate cancer.
Laura S Graham, Michael T Schweizer. Prostate 2022
0

Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma.
Valentin Benboubker, Félix Boivin, Stéphane Dalle, Julie Caramel. Front Immunol 2022
0

Heterogeneity of the tumor immune microenvironment and its clinical relevance.
Qingzhu Jia, Aoyun Wang, Yixiao Yuan, Bo Zhu, Haixia Long. Exp Hematol Oncol 2022
0

Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA.
Smita S Chandran, Jiaqi Ma, Martin G Klatt, Friederike Dündar, Chaitanya Bandlamudi, Pedram Razavi, Hannah Y Wen, Britta Weigelt, Paul Zumbo, Si Ning Fu,[...]. Nat Med 2022
1

Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance.
Aiping Zhang, Kai Miao, Heng Sun, Chu-Xia Deng. Int J Biol Sci 2022
0

Melanoma: An immunotherapy journey from bench to bedside.
Vishal Navani, Moira C Graves, Hiren Mandaliya, Martin Hong, Andre van der Westhuizen, Jennifer Martin, Nikola A Bowden. Cancer Treat Res 2022
0

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma.
Krisztian Homicsko, Reinhard Dummer, Christoph Hoeller, Jedd D Wolchok, F Stephen Hodi, James Larkin, Paolo A Ascierto, Victoria Atkinson, Caroline Robert, Michael A Postow,[...]. Cancers (Basel) 2022
0

The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors.
Melissa T Bu, Pallavi Chandrasekhar, Lizhong Ding, Willy Hugo. Pharmacol Ther 2022
0

Effect of stress-induced polyploidy on melanoma reprogramming and therapy resistance.
Svenja Meierjohann. Semin Cancer Biol 2022
2

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.
Wenjing Zhang, Fuyan Shi, Yujia Kong, Yuting Li, Chao Sheng, Suzhen Wang, Qinghua Wang. Cancer Med 2022
2

Targeting regulatory T cells in anti-PD-1/PD-L1 cancer immunotherapy.
Galina Zhulai, Eugenia Oleinik. Scand J Immunol 2022
2

Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition.
Meagan-Helen Henderson Berg, Sonia Victoria Del Rincón, Wilson H Miller. J Immunother Cancer 2022
1

Role of Hypoxia in the Interferon Response.
Esther Arnaiz, Adrian L Harris. Front Immunol 2022
0

Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling.
Georgi Apriamashvili, David W Vredevoogd, Oscar Krijgsman, Onno B Bleijerveld, Maarten A Ligtenberg, Beaunelle de Bruijn, Julia Boshuizen, Joleen J H Traets, Daniela D'Empaire Altimari, Alex van Vliet,[...]. Nat Commun 2022
0

Resistance Mechanisms to Anti-PD Cancer Immunotherapy.
Matthew D Vesely, Tianxiang Zhang, Lieping Chen. Annu Rev Immunol 2022
0

The translational challenges of precision oncology.
Oriol Pich, Chris Bailey, Thomas B K Watkins, Simone Zaccaria, Mariam Jamal-Hanjani, Charles Swanton. Cancer Cell 2022
0

HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab.
Andrea Ladányi, Barbara Hegyi, Tímea Balatoni, Gabriella Liszkay, Raphael Rohregger, Christoph Waldnig, József Dudás, Soldano Ferrone. Pathol Oncol Res 2022
1

Resistance mechanisms to immune checkpoints blockade by monoclonal antibody drugs in cancer immunotherapy: Focus on myeloma.
Alireza Isazadeh, Saba Hajazimian, Hamid Garshasbi, Behrouz Shadman, Amir Baghbanzadeh, Reza Chavoshi, Sina Taefehshokr, Mahdieh Farhoudi Sefidan Jadid, Khalil Hajiasgharzadeh, Behzad Baradaran. J Cell Physiol 2021
4

Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system.
Daniela Hirsch, Timo Gaiser, Kirsten Merx, Simone Weingaertner, Michael Forster, Alexander Hendricks, Matthias Woenckhaus, Thomas Schubert, Ralf-Dieter Hofheinz, Deniz Gencer. J Cancer Res Clin Oncol 2021
1

Joining Forces: Improving Clinical Response to Cellular Immunotherapies with Small-Molecule Inhibitors.
Debottam Sinha, Corey Smith, Rajiv Khanna. Trends Mol Med 2021
2

Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
Nikolaos Ioannou, Patrick R Hagner, Matt Stokes, Anita K Gandhi, Benedetta Apollonio, Mariam Fanous, Despoina Papazoglou, Lesley-Ann Sutton, Richard Rosenquist, Rose-Marie Amini,[...]. Blood 2021
14

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.
Denis L Jardim, Aaron Goodman, Debora de Melo Gagliato, Razelle Kurzrock. Cancer Cell 2021
72

Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade.
Kartik Sehgal, Andrew Portell, Elena V Ivanova, Patrick H Lizotte, Navin R Mahadevan, Jonathan R Greene, Amir Vajdi, Carino Gurjao, Tyler Teceno, Luke J Taus,[...]. J Clin Invest 2021
14

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.
Sreya Bagchi, Robert Yuan, Edgar G Engleman. Annu Rev Pathol 2021
124

Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy.
Vyara Matson, Carolina Soto Chervin, Thomas F Gajewski. Gastroenterology 2021
33

Emerging immunotherapies for metastasis.
Sarah C Edwards, Wilma H M Hoevenaar, Seth B Coffelt. Br J Cancer 2021
7


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy